カリディタス・セラピューティクスに関するコメント

$カリディタス・セラピューティクス(CALT.US)$
NEWS
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...

$カリディタス・セラピューティクス(CALT.US)$
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon c...

$カリディタス・セラピューティクス(CALT.US)$ Get some volume going!

$カリディタス・セラピューティクス(CALT.US)$ price target of 40,85$スーパー・マイクロ・コンピューター(SMCI.US)$tipranks.com/ne...

$カリディタス・セラピューティクス(CALT.US)$
📊⚡️📊

$カリディタス・セラピューティクス(CALT.US)$ Now thats a Full FDA approval pop! Hehehe

$カリディタス・セラピューティクス(CALT.US)$ Calliditas Therapeutics Shares Are Trading Higher After the Company Announced FDA Approval of TARPEYO